TrialArthritis research & therapy2026

No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials.

Sofia Ramiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.